Methods for Detecting Tumor Origin Based on MUC1, MUC2, and CK-17 Expression Levels
OwnerHai-Su Yang, Bruce Horten +1inventors
InventorsHai-Su Yang, Bruce Horten, Thomas Scholl
Life of this patent
Estimating the term…
Abstract
Methods and compositions for detecting tumor origin are disclosed. In certain embodiments, the origin is determined by detecting expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), cytokeratin 17 (CK17), or a combination thereof. Also disclosed are methods for aiding in the determination of an appropriate course of treatment for a subject with a tumor, or for predicting a therapeutic outcome of a subject, based on the expression levels of MUC1, MUC2, CK17, or a combination thereof. Kits for use in each of these methods are also provided.
Claims22
A method of detecting origin of a tumor, comprising:
- (a) detecting, in a biological sample obtained from a subject, expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), and cytokeratin 17 (CK17);
- (b) comparing expression levels of MUC1, MUC2, and CK17 to a control;
- and
- (c) determining the origin of the tumor based on the detected expression levels.
A method for aiding a physician in determining an appropriate treatment for a patient with adenocarcinoma comprising:
- detecting, in a biological sample obtained from the patient, expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), and cytokeratin 17 (CK17), as compared to controls;
- determining the origin of the tumor based on the detected expression levels of MUC1, MUC2, and CK17;
- and
- reporting the determination of the origin of the tumor to the physician.
A kit for detecting origin of a tumor, comprising:
- a set of reagents that specifically detects expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), and cytokeratin 17 (CK17).
Dependencies are inferred from the claim text.